Sugi Predict

Sugi Predict / Compounds / SCHEMBL7182069

SCHEMBL7182069

SCHEMBL7182069

Cc1cc(OCCC(C)C)ccc1PC(=O)c1c(Cl)cccc1Cl.[LiH]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.41
▸ S1PR5 Q9H228 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NR1H4 Q96RI1 2/20 0.39
▸ GALR3 O60755 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ MCL1 Q07820 2/20 0.38
▸ PPARG P37231 2/20 0.38
▸ PPARD Q03181 2/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ MRGPRX4 Q96LA9 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TDP1 Q9NUW8 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177558 0.97 S1PR1 (0.39) S1PR1S1PR5MAPK1EPHX2MEN1
SCHEMBL7181389 0.94 ALDH1A1 (0.38) S1PR1S1PR5MAPK1EPHX2MEN1
SCHEMBL7187020 0.91 MAPK1 (0.43) S1PR1S1PR5MAPK1EPHX2MEN1
SCHEMBL7189819 0.89 S1PR1 (0.41) S1PR1S1PR5MAPK1EPHX2MEN1
SCHEMBL7176019 0.88 KMT2A (0.41) MEN1PKMKMT2ANR1H4MCL1
SCHEMBL7188683 0.88 S1PR1 (0.38) S1PR1S1PR5MAPK1EPHX2MEN1
SCHEMBL7187530 0.87 PPARG (0.42) MCL1PPARGPPARDMRGPRX4SMN1; SMN2
SCHEMBL7174697 0.87 KMT2A (0.43) KMT2AMCL1PPARGPPARDMRGPRX4
SCHEMBL7183100 0.87 MAPK1 (0.40) S1PR1S1PR5MAPK1EPHX2NR1H4
SCHEMBL7187971 0.86 MAPK1 (0.43) S1PR1S1PR5MAPK1EPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 S1PR1 549/4885S1PR5 716/4885MAPK1 1801/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 S1PR1 703/4885S1PR5 932/4885MAPK1 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.